Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.51 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23377075 | 0.91 | SLC6A4 (0.49) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL8851344 | 0.90 | SLC6A2 (0.46) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL8851445 | 0.90 | SLC6A2 (0.46) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL21517042 | 0.90 | SLC6A4 (0.46) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL23988720 | 0.90 | SLC6A2 (0.47) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL8851427 | 0.90 | SLC6A2 (0.49) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL13019287 | 0.90 | SLC6A4 (0.46) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL8851000 | 0.88 | SLC6A4 (0.44) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL24743252 | 0.87 | SLC6A4 (0.43) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL8851948 | 0.87 | SLC6A2 (0.43) | SLC6A2SLC6A4NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466375-A | Substituted azaspiro derivatives | NEUROGEN CORP (US) | 2009-06-24 | — | — | CN | claimed |
| CN-112194691-B | Method for preparing catalpol and its derivative based on radix rehmanniae Preparata and application | 河北仁心药业有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-11833771-B2 | Method for making photochromic contact lenses | ALCON INC. (CH) | 2023-12-05 | — | — | US | disclosed |
| WO-2022100710-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-05-19 | — | — | WO | disclosed |
| EP-3383877-B1 | HETEROCYCLE COMPOUNDS AND USES THEREOF | ZHEJIANG JIANFENG YIEN BIOTECHNOLOGY CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-112194691-A | Method for preparing catalpol and catalpol derivative based on radix rehmanniae preparata and application of catalpol derivative | 河北仁心药业有限公司 | 2021-01-08 | — | — | CN | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| EP-2300013-B1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMA INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| CN-103130709-B | 3-aminopropionic acid piperidine amide compound with HIV activity, synthetic method and application | 常州亚邦制药有限公司 | 2017-04-12 | — | — | CN | disclosed |
| US-20080096868-A1 | 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| CN-101098873-A | 1, 4-substituted pyrazolopyrimidines as kinase inhibitors | NOVARTIS AG (CH) | 2008-01-02 | — | — | CN | disclosed |
| US-20070208033-A1 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208033-A1 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1812441-A1 | 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-7176227-B2 | For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis | KUREHA CORPORATION (JP) | 2007-02-13 | — | — | US | disclosed |
| WO-2006050946-A1 | 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-05-18 | — | — | WO | disclosed |
| US-20050165063-A1 | Amine compounds and use thereof | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1550657-A1 | AMINE COMPOUNDS AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | SLC6A2 3389/4885SLC6A4 3172/4885NOS2 4373/4885 |
| US-20050165063-A1 | Amine compounds and use thereof | NR0B2, NR5A2, NR1H4 | SLC6A2 613/4885SLC6A4 1423/4885NOS2 2165/4885 |
| US-20080096868-A1 | 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors | MAP3K1, MAP4K2, MAP4K5 | SLC6A2 4736/4885SLC6A4 4069/4885NOS2 3119/4885 |
| US-20070208033-A1 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | CXCR4, CXCR6, CCR5 | SLC6A2 1579/4885SLC6A4 2324/4885NOS2 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.